Capsulation NanoScience Earns Innovation Award

Frost & Sullivan (Palo Alto, CA, USA), an international growth consultancy firm, recently awarded the 2005 "Product Differentiation Innovation Award” in the global nanobiotechnology market to Capsulation NanoScience AG (Berlin, Germany).

The company received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications. Capsulation has also created innovative drug delivery systems for pharmaceutically active substances. Enclosed in tiny nanocapsules, these can be safely delivered to the specified site of action in the human body.

"We are very delighted about the award since it demonstrates that we have considerably advanced our vision to develop innovative and highly specialized products on the basis of the LBL-Technology,” stated Alexander Herrmann, CFO of Capsulation NanoScience.

Capsulation's range of products is based on the proprietary LBL-Technology (layer-by-layer)--a technique of producing polymeric nanocapsules. This encapsulation system is very versatile; various polymers can be applied to encapsulate drugs as well as other chemical substances. Furthermore, the outside of the capsule may be functionalized through the addition of targeting molecules such as monoclonal antibodies.

The LBL-Tehcnology platform will soon be utilized for a broad range of applications. LBL-Solv is a means of drug reformulation, where water-insoluble active compounds are nano-encapsulated to increase their bioavailability. In addition, LBL-Intra is an application specific to intracellular drug delivery. The capsules may also be applied to improve the function of drug-releasing implants.

Capsulation is also developing and expanding its nano-diagnostics capabilities, most in cooperation with industry partners. The LBL nanocapsules can help in the detection of DNA or the diagnoses of disease.





Related Links:
Capsulation NanoScience
Frost & Sullivan